Navigation Links
Circulatory Disorder Not Studied Enough in Women, Experts Say
Date:2/15/2012

WEDNESDAY, Feb. 15 (HealthDay News) -- Even though it increases the risk of heart attack or stroke, peripheral artery disease is often unrecognized and untreated in women, according to an American Heart Association scientific statement released Wednesday.

Peripheral artery disease is a circulatory disorder caused by a buildup of fat and other materials in the blood vessels outside the heart, usually in the legs, feet and arms. If untreated, it can increase heart attack and stroke risk, severely limit walking ability, and cause tissue death that leads to limb amputation.

Because women with peripheral artery disease have a twofold to threefold increased risk of stroke or heart attack, health care providers should educate and test women at risk for peripheral artery disease, the statement advised. It also called for more female-focused research into the disease.

There are too few women enrolled in studies to provide a clear understanding of how the disease progresses, or to accurately determine the incidence and prevalence of peripheral artery disease in women, according to the statement authors.

More studies of peripheral artery disease specifically in women are needed, and results from previous studies should be pooled to obtain an adequate sample size of women, they recommended.

The authors also called for research to help determine how gender may affect the rate of development of peripheral artery disease, response to medications, and potential benefits of vessel-opening procedures.

All heart-health promotion campaigns should provide specific education about peripheral artery disease screening and treatment in women, the authors added.

The statement is published Feb. 15 in the journal Circulation.

Peripheral artery disease affects about 8 million people in the United States, with nearly equal prevalence among women and men.

"The rate of deaths and the health care costs associat
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. People with anxiety disorder less able to regulate response to negative emotions, study shows
2. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
3. Tennessee Orofacial Myology, LLC is the First Office to Open in Tennessee to Help Patients with Orofacial Disorders
4. Anxiety Disorder Patients Process Emotions Differently
5. Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D.
6. Remuda Ranch Programs for Eating and Anxiety Disorders Sponsors a Special Edition of the Award-Winning Documentary America The Beautiful
7. Visual Cues that Improve Walking for People with Movement Disorders - Study Shows Small Change in Arrangement Can Make a Big Difference in Improvement Gained
8. A mothers sensitivity may help language growth in children with autism spectrum disorder
9. Montecatini Eating Disorders Program Announces 'Log In & Learn' Webinar Series for Treatment Professionals
10. Genetic cause discovered for rare bleeding disorder
11. NIAID media availability: Food allergy-related disorder linked to master allergy gene
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Circulatory Disorder Not Studied Enough in Women, Experts Say
(Date:12/21/2014)... Portland, OR (PRWEB) December 21, 2014 ... discussing some of the issues and systemic barriers for ... ITU World Paratriathlon Champion. Scheidies has a condition called ... over time. He describes how he adapted his athletic ... to use his success in triathlon to pioneer the ...
(Date:12/21/2014)... OH (PRWEB) December 21, 2014 As ... men alleging heart attacks, stroke and blood clots from ... to increase, a new study shows that the male ... colon cancer. In a study published in the Proceedings ... researcher, James Amos-Landgraf examined a group of male rats ...
(Date:12/21/2014)... December 21, 2014 The Oncology Institute of ... the Santa Ana and Whittier offices. The Hope for the ... lives of patients and their families during the holiday season. ... to approximately 70 children between both offices. This event continues ... of Target’s community service team, store managers and assistant managers ...
(Date:12/20/2014)... 21, 2014 BambooIndustry.com is a professional ... . The business has recently shown its new engineered ... all its bamboo flooring models. , BambooIndustry.com’s customers come ... Asia and more. According to the CEO of the ... very fast in the past few years, and the ...
(Date:12/20/2014)... 21, 2014 MissyDress, a distinguished special ... prom lovers. The business has drastically cut prices to ... to everyone until Jan. 30, 2015. Many of the ... dresses, V-neck dresses, lace dresses, and more. , A ... there every day. Whether A-line princess prom dresses or ...
Breaking Medicine News(10 mins):Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2
... of ... Hematology 2007, SINGAPORE, Dec. ... most advanced compounds at The American Society of,Hematology 49th Annual Meeting ... and selective JAK2 inhibitor SB1518,highlighted the therapeutic potential of SB1518 for ...
... SAN JOSE, Calif., Dec. 10 Human Pheromone ... Company") today announced,today that its Board of Directors ... of common stock, representing approximately 10% of the,current ... open market and,private transactions. The plan sets no ...
... 90 mg, * 53% of Patients Treated with 90 mg ... Reduction in the Risk of Death ... Compared to Non-responders, ATLANTA, Dec. 10 ... maturing data,from the Phase 1/2 study investigating the combined use of MGCD0103, ...
... (Nasdaq: MLNM ) today reported the presentation ... III clinical trial, comparing,VELCADE and dexamethasone (VcD) to ... by the Intergroupe,Francophone du Myelome (IFM) cooperative group ... at the American Society of Hematology (ASH) 49th,Annual ...
... Calls to Quitline, EAGAN, Minn., Dec. 10 ... of Minnesota (Blue Cross), recorded that more of,its members ... enrollment,data reported by Blue Cross, telephone coaching quitline. Stop-smoking,quitline ... in October,2007 -- nearly a 43 percent increase. This ...
... the past 30 years,the San Antonio Breast Cancer ... among scientists and clinicians from around the world, ... providing an ideal format for,scientists to present, for ... as,well as other pertinent information, including diagnostic developments., ...
Cached Medicine News:Health News:S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders 2Health News:S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders 3Health News:Human Pheromone Sciences Announces Stock Repurchase Program 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 7Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 2Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 3Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 4Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 5Health News:VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial 6Health News:Blue Cross' Stop Smoking Phone Coaching Enrollments Jumped in October 2Health News:San Antonio Breast Cancer Symposium December 13th to 16th 2007 2
(Date:12/19/2014)... WORTH, Texas , December 18, 2014 /PRNewswire/ ... a networked software application/module that is used to ... related images. RIS comprises a patient tracking and ... system. The integration of RIS with HIS and ... used for patient registration and patient scheduling, patient ...
(Date:12/19/2014)... REDWOOD CITY, Calif., Dec. 18, 2014 ... on the development of medical diagnostics based on ... of gas flow, today announced financial results for ... 30, 2014. "Following the completion of ... well positioned to maximize the recently initiated CoSense® ...
(Date:12/19/2014)... , Dec. 19, 2014  Eli Lilly and ... Paris: FR0011184241 – ADOC) today announced a worldwide licensing ... BioChaperone Lispro, for treatment in people with type 1 ... proprietary BioChaperone® technology and is currently in Phase Ib ... Lispro with the goal of optimizing glucose levels during ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... , MORRISTOWN, N.J. , May 24 Watson ... subsidiary, Watson Laboratories, Inc., has received approval from the United States ... for Valacyclovir Hydrochloride tablets, USP, in the 500 and 1000 mg ... to begin shipping the product shortly.   , ...
... Genzyme Corp. has signed a consent decree agreeing to correct manufacturing quality violations at ... government $175 million in unlawful profits from the sale of products that ... , , ... , , ...
Cached Medicine Technology:Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 2Watson's Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval 3Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 2Genzyme Corp. Signs Consent Decree to Correct Violations at Allston, Mass., Manufacturing Plant and Give up $175 Million in Profits 3
BD Vacutainer® Specialty Tubes - Trace Element - Plastic...
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: